Cingulate Inc
CING3.540USD
+0.020+0.57%
Fechamento 09/19, 16:00（ET）Cotações atrasadas em 15 min
17.31MValor de mercado
PerdaP/L TTM
Mais detalhes de Cingulate Inc Empresa
Cingulate Inc. is a biopharmaceutical company. The Company is focused on the development, manufacturing, and commercialization of pharmaceutical products that utilize its precision timed release (PTR) drug delivery platform technology to create dosing schedules and drug release profiles. It focuses on the treatment of attention deficit/hyperactivity disorder (ADHD). The Company is in the development of two lead product candidates, such as CTx-1301 (dexmethylphenidate) and CTx-1302 (dextroamphetamine). The Company’s CTx-1301 and CTx-1302 are being developed for the treatment of ADHD in the three core patient segments: children (ages 6-12), adolescents (ages 13-17), and adults (ages18+). In addition, the Company has a third product to treat anxiety, CTx-2103, in a formulation stage. Its CTx-1301, CTx-1302 and CTx-2103 drug candidates contain three releases of active pharmaceutical ingredient combined into one small tablet dosage form.
Informações da empresa
Código da empresaCING
Nome da EmpresaCingulate Inc
Data de listagemOct 07, 2021
CEOMs. Jennifer L. Callahan
Número de funcionários13
Tipo de títulosOrdinary Share
Fim do ano fiscalOct 07
Endereço1901 W. 47Th Place
CidadeKANSAS CITY
Bolsa de valoresNASDAQ Capital Market Consolidated
PaísUnited States of America
Código postal66205
Telefone19139422300
Sitehttps://www.cingulate.com/
Código da empresaCING
Data de listagemOct 07, 2021
CEOMs. Jennifer L. Callahan
Executivos da empresa
Nome
Nome/Posição
Posição
Ações detidas
Variação
Mr. Bryan Lawrence
Mr. Bryan Lawrence
Independent Director
Independent Director
--
--
Mr. Thomas Dalton
Mr. Thomas Dalton
Vice President, Investor and Public Relations
Vice President, Investor and Public Relations
--
--
Mr. John A. (Jay) Roberts
Mr. John A. (Jay) Roberts
Executive Chairman of the Board
Executive Chairman of the Board
--
--
Dr. Raul R. Silva, M.D.
Dr. Raul R. Silva, M.D.
Co-Founder, Executive Vice President, Chief Science Officer
Co-Founder, Executive Vice President, Chief Science Officer
--
--
Ms. Jennifer L. Callahan
Ms. Jennifer L. Callahan
Interim Chief Executive Officer, Chief Financial Officer
Interim Chief Executive Officer, Chief Financial Officer
--
--
Mr. Jeffrey S. (Jeff) Ervin
Mr. Jeffrey S. (Jeff) Ervin
Independent Director
Independent Director
--
--
Dr. Matthew N. (Matt) Brams, M.D.
Dr. Matthew N. (Matt) Brams, M.D.
Co-Founder, Executive Vice President, Chief Medical Officer
Co-Founder, Executive Vice President, Chief Medical Officer
--
--
Mr. Nilay Patel, J.D.
Mr. Nilay Patel, J.D.
Chief Legal Officer
Chief Legal Officer
--
--
Mr. Peter J. Werth
Mr. Peter J. Werth
Director
Director
--
--
Nome
Nome/Posição
Posição
Ações detidas
Variação
Mr. Bryan Lawrence
Mr. Bryan Lawrence
Independent Director
Independent Director
--
--
Mr. Thomas Dalton
Mr. Thomas Dalton
Vice President, Investor and Public Relations
Vice President, Investor and Public Relations
--
--
Mr. John A. (Jay) Roberts
Mr. John A. (Jay) Roberts
Executive Chairman of the Board
Executive Chairman of the Board
--
--
Dr. Raul R. Silva, M.D.
Dr. Raul R. Silva, M.D.
Co-Founder, Executive Vice President, Chief Science Officer
Co-Founder, Executive Vice President, Chief Science Officer
--
--
Ms. Jennifer L. Callahan
Ms. Jennifer L. Callahan
Interim Chief Executive Officer, Chief Financial Officer
Interim Chief Executive Officer, Chief Financial Officer
--
--
Mr. Jeffrey S. (Jeff) Ervin
Mr. Jeffrey S. (Jeff) Ervin
Independent Director
Independent Director
--
--
Detalhamento da receita
Sem dados
Sem dados
Por Empresa
Por Região
Sem dados
Distribuição de ações
Atualizado em: ter, 19 de ago
Atualizado em: ter, 19 de ago
Investidores
Tipos de investidores
Investidores
Investidores
Proporção
Commonwealth Financial Network
2.15%
Werth Family Investment Associates LLC
1.75%
The Vanguard Group, Inc.
0.63%
Susquehanna International Group, LLP
0.59%
Geode Capital Management, L.L.C.
0.57%
Outro
94.31%
Investidores
Investidores
Proporção
Commonwealth Financial Network
2.15%
Werth Family Investment Associates LLC
1.75%
The Vanguard Group, Inc.
0.63%
Susquehanna International Group, LLP
0.59%
Geode Capital Management, L.L.C.
0.57%
Outro
94.31%
Tipos de investidores
Investidores
Proporção
Investment Advisor
4.09%
Corporation
1.81%
Investment Advisor/Hedge Fund
0.57%
Research Firm
0.38%
Venture Capital
0.20%
Hedge Fund
0.03%
Outro
92.93%
Participação acionária institucional
Atualizado em: ter, 1 de jul
Atualizado em: ter, 1 de jul
Período do relatório
N.º de instituições
Ações detidas
Proporção
Variação
2025Q2
44
305.06K
5.93%
+1.66K
2025Q1
47
242.60K
6.03%
-49.04K
2024Q4
47
197.43K
6.15%
-35.64K
2024Q3
47
156.73K
4.97%
-40.96K
2024Q2
44
186.43K
34.55%
+67.80K
2024Q1
47
54.28K
18.74%
+25.73K
2023Q4
45
21.28K
29.79%
-7.47K
2023Q3
42
26.64K
41.94%
+1.78K
2023Q2
36
15.08K
30.98%
-2.19K
2023Q1
34
15.09K
32.03%
-921.00
Ver Mais
Atividade dos acionistas
Nome
Ações detidas
Proporção
Variação
Var. %
Data
Commonwealth Financial Network
55.52K
1.31%
+12.50K
+29.05%
Mar 31, 2025
Werth Family Investment Associates LLC
97.99K
2.31%
--
--
Apr 14, 2025
The Vanguard Group, Inc.
10.76K
0.25%
+8.76K
+438.54%
Mar 31, 2025
Geode Capital Management, L.L.C.
30.40K
0.72%
+3.08K
+11.26%
Mar 31, 2025
UBS Financial Services, Inc.
22.12K
0.52%
+9.92K
+81.34%
Mar 31, 2025
Quantum Private Wealth, LLC
10.00K
0.24%
+10.00K
--
Mar 31, 2025
Ver Mais
ETFs Relacionados
Nome
Proporção
Sem dados
Dividendo
Um total de
0.00
USD foi distribuído em dividendos nos últimos 5 anos.
Data
Dividendo
Data de registro
Data de pagamento
Data ex-dividendo
Sem dados
Desdobramento de ações
Data
Tipo
Proporção
Aug 07, 2024
Merger
12→1
Aug 07, 2024
Merger
12→1
Aug 07, 2024
Merger
12→1
Aug 07, 2024
Merger
12→1
Nov 28, 2023
Merger
20→1
Nov 28, 2023
Merger
20→1
Data
Tipo
Proporção
Aug 07, 2024
Merger
12→1
Aug 07, 2024
Merger
12→1
Aug 07, 2024
Merger
12→1
Aug 07, 2024
Merger
12→1
Nov 28, 2023
Merger
20→1
Nov 28, 2023
Merger
20→1
Nov 28, 2023
Merger
20→1
Nov 28, 2023
Merger
20→1
